Phathom Pharmaceuticals, Inc. PHAT
5.91 USD -0.32 (-5.10%)
Nov 13, 2026, 12:42 PM EST
5.78 Day range 6.24
5.02 52-week range 18.31
- YTD
- -64.36%
- 1 year
- -60.19%
News
zacks.com Implied Volatility Surging for Phathom Pharmaceuticals Stock Options Investors need to pay close attention to PHAT stock based on the movements in the options market lately.
benzinga.com Phathom Pharmaceuticals Announces $0 Payment From Eligible Commercially Insured Patients For VOQUEZNA Tablets Through BlinkRx Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal diseases, today announced that eligible…
benzinga.com Phathom Pharmaceuticals Q3 2026 Earnings Call Transcript Phathom Pharmaceuticals (NASDAQ:PHAT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $310.000M-$325.000M vs $314.842M Est Phathom Pharmaceuticals (NASDAQ:PHAT) affirms FY2026 sales outlook from $310.000 million-$325.000 million to $310.000 million-$325.000 million vs $314.842 million estimate.
benzinga.com Phathom Pharmaceuticals Q3 Adj. EPS $0.04 Beats $0.02 Estimate, Sales $84.722M Miss $85.096M Estimate Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.02 by 100 percent. This is a 126.67 percent increase over losses…- benzinga.com Phathom Pharmaceuticals To Present New Cost-Effectiveness Data For VOQUEZNA At The American College Of Gastroenterology Meeting, October 9-14; New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at…
benzinga.com Phathom Pharmaceuticals Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERD Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results…
benzinga.com Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10 Leerink Partners analyst Daniel Clark initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Market Perform rating and announces Price Target of $10.
benzinga.com Barclays Maintains Overweight on Phathom Pharmaceuticals, Lowers Price Target to $14 Barclays analyst Glen Santangelo maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Overweight and lowers the price target from $18 to $14.- benzinga.com Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22 Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.
benzinga.com HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.- benzinga.com Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22 Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $28 to $22.
- benzinga.com Phathom Pharmaceuticals Q2 Adj. EPS $0.00 Beats $(0.25) Estimate, Sales $74.300M Beat $72.789M Estimate Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.25) by 100 percent. This is a 100 percent increase over losses of…
- benzinga.com Phathom Pharmaceuticals Lowers FY2026 Sales Guidance from $320.000M-$345.000M to $310.000M-$325.000M vs $332.196M Est Phathom Pharmaceuticals (NASDAQ:PHAT) lowers FY2026 sales outlook from $320.000 million-$345.000 million to $310.000 million-$325.000 million vs $332.196 million estimate.
benzinga.com Phathom Pharmaceuticals Q2 Sales $74.300M Beat $72.789M Estimate Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly sales of $74.300 million which beat the analyst consensus estimate of $72.789 million by 2.08 percent. This is a 88.09 percent increase over…
benzinga.com Phathom Pharmaceuticals Completes Patient Enrollment In Its Phase 2 pHalcon-EoE-201 Clinical Study Of VOQUEZNA Tablets To Treat Eosinophilic Esophagitis In Adults Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced it has…- benzinga.com HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
benzinga.com Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript 
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $320.000M-$345.000M vs $331.417M Est Phathom Pharmaceuticals (NASDAQ:PHAT) affirms FY2026 sales outlook from $320.000 million-$345.000 million to $320.000 million-$345.000 million vs $331.417 million estimate.
- benzinga.com Phathom Pharmaceuticals Q1 Adj. EPS $(0.18) Beats $(0.32) Estimate, Sales $58.301M Beat $57.028M Estimate Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.32) by 43.75 percent. This is a 83.18 percent increase over…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com This Argan Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday Top Wall Street analysts upgraded PHAT and PWR, while AGX was upgraded to Overweight with a $550 price target. Check out analysts' views on these stocks.- benzinga.com Barclays Upgrades Phathom Pharmaceuticals to Overweight, Raises Price Target to $18 Barclays analyst Glen Santangelo upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) from Equal-Weight to Overweight and raises the price target from $16 to $18.
- benzinga.com Guggenheim Maintains Buy on Phathom Pharmaceuticals, Raises Price Target to $25 Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and raises the price target from $20 to $25.
- benzinga.com Phathom Pharmaceuticals Sees FY2026 Sales $320.000M-$345.000M vs $314.481M Est Phathom Pharmaceuticals (NASDAQ:PHAT) sees FY2026 sales of $320.000 million-$345.000 million vs $314.481 million analyst estimate.
benzinga.com Phathom Pharmaceuticals Earnings Review: Q4 Summary - benzinga.com Phathom Pharmaceuticals Q4 Adj. EPS $(0.08) Beats $(0.38) Estimate, Sales $57.584M Beat $57.050M Estimate Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.38) by 79 percent. This is a 89.87 percent increase over losses…
- benzinga.com Earnings Scheduled For February 26, 2026
benzinga.com Phathom Pharma Shows Sales Strength, Targets 2026 Profitability Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million.
benzinga.com Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) (Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the story.) U.S. stock futures declined on Thursday following a mixed close on Tuesday, with only the…
benzinga.com Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - benzinga.com Phathom Pharmaceuticals Expects Q4 Net Revenues Of ~$57M-$58M And FY25 Net Revenues Of ~$174.5M-$175.5M Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced certain…
- benzinga.com Phathom Pharmaceuticals Files For Mixed Shelf Offering; Size Not Disclosed Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell the securities identified above from time to time in one or more offerings. This prospectus provides you with a general…
benzinga.com Earnings Scheduled For October 30, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For August 7, 2025
benzinga.com Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday 
benzinga.com Palo Alto Networks, Take-Two Interactive Software, VF Corp And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Earnings Scheduled For May 1, 2025
- benzinga.com Earnings Scheduled For March 6, 2025
- benzinga.com Earnings Scheduled For March 7, 2024 Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million.
- benzinga.com Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday U.S. stocks were mostly lower, with the Nasdaq Composite falling more than 200 points on Tuesday.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers SCYNEXIS, Inc. (NASDAQ: SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront…
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 469 companies hit new 52-week lows.